Understanding HER2-Low mBC

ESMO 2022 Conference Coverage
N

ESMO 2022 on DESTINY-Breast04 Patient-Reported Outcomes: T-DXd vs. TPC in HER2-Low mBC

By ESMO 2022 Conference Coverage FEATURING Naoto Ueno
By ESMO 2022 Conference Coverage FEATURING Naoto Ueno
480 views
October 3, 2022
0 Comments
Login to view comments. Click here to Login
14:22

Defining and Identifying HER2-Low Breast Cancer

Winship Cancer Institute - Emory University

J. Meisel

277 views
10:21

Novel ADCs for Management of mBC

ecancer

H. Rugo

582 views
07:13

Overview of the Management of HER2-Low Breast Cancer Patients

ecancer

H. Rugo

357 views
06:46

2023 Updates on HER2-Low Breast Cancer

ecancer

S. Al Sukhun

223 views
29:53

Advances in Treatment of HER2+ BC in 2023

Keck School of Medicine of USC

W. Gradishar

415 views
13:32

Impact of DESTINY-Breast04 Data in HER2-Low Breast Cancer: How to Im…

Dana-Farber Cancer Institute

P. Tarantino

959 views
03:14

SABCS 2022: Comprehensive Genomic Characterization of HER2-Low Breas…

SABCS 2022 Conference Coverage

P. Tarantino

355 views
06:51

SABCS 2022: Genomic and Transcriptomic Landscape of HER2-Low Breast …

SABCS 2022 Conference Coverage

R. Bansal

92 views
15:50

Management of HR+/HER2- Advanced BC: Future Directions

Susan Dent

764 views
05:51

The New Paradigm of HER2-Low Breast Cancer

Penn Medicine Abramson Cancer Center

M. Mahler

205 views